599 related articles for article (PubMed ID: 12744370)
1. Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion.
Trouillas J; Daniel L; Guigard MP; Tong S; Gouvernet J; Jouanneau E; Jan M; Perrin G; Fischer G; Tabarin A; Rougon G; Figarella-Branger D
J Neurosurg; 2003 May; 98(5):1084-93. PubMed ID: 12744370
[TBL] [Abstract][Full Text] [Related]
2. Polysialylated-neural cell adhesion molecule expression in rat pituitary transplantable tumors (spontaneous mammotropic transplantable tumor in Wistar-Furth rats) is related to growth rate and malignancy.
Daniel L; Trouillas J; Renaud W; Chevallier P; Gouvernet J; Rougon G; Figarella-Branger D
Cancer Res; 2000 Jan; 60(1):80-5. PubMed ID: 10646857
[TBL] [Abstract][Full Text] [Related]
3. Expression of E-cadherin, Slug and NCAM and its relationship to tumor invasiveness in patients with acromegaly.
Mendes GA; Haag T; Trott G; Rech CGSL; Ferreira NP; Oliveira MC; Kohek MB; Pereira-Lima JFS
Braz J Med Biol Res; 2017 Dec; 51(2):e6808. PubMed ID: 29267504
[TBL] [Abstract][Full Text] [Related]
4. [Expression of polysialylated NCAM on neuroblastomas of various histology and clinical stages].
Glüer S; Zense M; Radtke E; von Schweinitz D
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):289-92. PubMed ID: 14518262
[TBL] [Abstract][Full Text] [Related]
5. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
6. A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.
Wierinckx A; Auger C; Devauchelle P; Reynaud A; Chevallier P; Jan M; Perrin G; Fèvre-Montange M; Rey C; Figarella-Branger D; Raverot G; Belin MF; Lachuer J; Trouillas J
Endocr Relat Cancer; 2007 Sep; 14(3):887-900. PubMed ID: 17914117
[TBL] [Abstract][Full Text] [Related]
7. Computational analysis identifies invasion-associated genes in pituitary adenomas.
Cao C; Wang W; Ma C; Jiang P
Mol Med Rep; 2015 Aug; 12(2):1977-82. PubMed ID: 25824863
[TBL] [Abstract][Full Text] [Related]
8. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
9. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
[TBL] [Abstract][Full Text] [Related]
11. Polysialylated NCAM represses E-cadherin-mediated cell-cell adhesion in pancreatic tumor cells.
Schreiber SC; Giehl K; Kastilan C; Hasel C; Mühlenhoff M; Adler G; Wedlich D; Menke A
Gastroenterology; 2008 May; 134(5):1555-66. PubMed ID: 18384787
[TBL] [Abstract][Full Text] [Related]
12. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
13. Metalloproteinases ADAM12 and MMP-14 are associated with cavernous sinus invasion in pituitary adenomas.
Wang J; Voellger B; Benzel J; Schlomann U; Nimsky C; Bartsch JW; Carl B
Int J Cancer; 2016 Sep; 139(6):1327-39. PubMed ID: 27144841
[TBL] [Abstract][Full Text] [Related]
14. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery.
Meij BP; Lopes MB; Ellegala DB; Alden TD; Laws ER
J Neurosurg; 2002 Feb; 96(2):195-208. PubMed ID: 11838791
[TBL] [Abstract][Full Text] [Related]
15. New WHO classification of pituitary adenomas (4th edition): assessment of pituitary transcription factors and the prognostic histological factors.
Nishioka H; Inoshita N
Brain Tumor Pathol; 2018 Apr; 35(2):57-61. PubMed ID: 29318396
[TBL] [Abstract][Full Text] [Related]
16. Polysialic acid neural cell adhesion molecule (PSA-NCAM) is an adverse prognosis factor in glioblastoma, and regulates olig2 expression in glioma cell lines.
Amoureux MC; Coulibaly B; Chinot O; Loundou A; Metellus P; Rougon G; Figarella-Branger D
BMC Cancer; 2010 Mar; 10():91. PubMed ID: 20219118
[TBL] [Abstract][Full Text] [Related]
17. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
[TBL] [Abstract][Full Text] [Related]
18. The minimal structural domains required for neural cell adhesion molecule polysialylation by PST/ST8Sia IV and STX/ST8Sia II.
Close BE; Mendiratta SS; Geiger KM; Broom LJ; Ho LL; Colley KJ
J Biol Chem; 2003 Aug; 278(33):30796-805. PubMed ID: 12791681
[TBL] [Abstract][Full Text] [Related]
19. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
20. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]